


PHARMACEUTICAL 2022

zymeworks

Zymeworks BC Inc. Rank 278 of 466





PHARMACEUTICAL 2022



Zymeworks BC Inc. Rank 278 of 466

The relative strengths and weaknesses of Zymeworks BC Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zymeworks BC Inc. compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 12% points. The greatest weakness of Zymeworks BC Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 82%, being 3.9% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	288,220
Cost of Goods Sold	0
Intangible Assets	15,854
Liabilities, Current	71,853
Liabilities, Non-Current	33,671
Other Assets	62,275
Other Compr. Net Income	0
Other Expenses	-516
Other Liabilities	34,514
Other Net Income	3,274
Other Revenues	26,680
Property and Equipment	22,783
Research and Development	199,752
Selling, General and Administrative Expense	42,561

Output Variable	Value in 1000 USD
Assets	389,132
Liabilities	140,038
Expenses	241,797
Revenues	26,680
Stockholders Equity	249,094
Net Income	-211,843
Comprehensive Net Income	-211,843
Economic Capital Ratio	82%

